Can natural antibodies to VIP or VIP-like HIV-1 glycoprotein facilitate prevention and supportive treatment of breast cancer?
No Thumbnail
Authors
Veljković, MilenaBranch, Donald R.
Dopsaj, Violeta
Veljković, Veljko
Veljković, Nevena V.
Glišić, Sanja
Colombatti, Alfonso
Article
Metadata
Show full item recordAbstract
Objectives: The incidence of non-AIDS-defining cancer is remarkably higher in HIV-infected than in the general population. In contrast, breast cancer risk is significantly reduced in the HIV-infected population. The molecular mechanisms underlying the phenomenon of suppression of breast cancer in the HIV-infected population may serve as a basis for development of a new platform for prevention and treatment of breast cancer. Hypothesis: Various evidences indicate that vasoactive intestinal peptide (VIP) plays an important role in growth, and differentiation of breast cancer. We previously showed (i) that natural antibodies recognizing VIP and the gp120-derived peptide NTM significantly contribute to the control of HIV disease progression by suppression of VIP-like activity of HIV-1 gp120 and (ii) that physical exercise stimulates production of these natural antibodies. These findings suggest that natural anti-VIP/NTM antibodies could contribute to a decrease of breast cancer in the HIV-...infected population by suppression of VIP, which may play a pro/oncogenic function. Aerobic exercise which stimulates production of anti-VIP/NTM antibodies could be used as prevention and supportive treatment of breast cancer. Impact: Immunotherapy based on natural anti-VIP/NTM antibodies could serve as an effective adjunct therapy for the treatment of breast cancer. Similarly, aerobic exercise, which stimulates production of these antibodies, should be considered as an inexpensive and safe preventive and supportive breast cancer therapy. Natural anti-VIP/NTM antibodies also represent promising prognostic marker for breast cancer. (C) 2011 Elsevier Ltd. All rights reserved.
Source:
Medical Hypotheses, 2011, 77, 3, 404-408Funding / projects:
DOI: 10.1016/j.mehy.2011.05.030
ISSN: 0306-9877
PubMed: 21684085
WoS: 000295183500022
Scopus: 2-s2.0-80051805630
Collections
Institution/Community
VinčaTY - JOUR AU - Veljković, Milena AU - Branch, Donald R. AU - Dopsaj, Violeta AU - Veljković, Veljko AU - Veljković, Nevena V. AU - Glišić, Sanja AU - Colombatti, Alfonso PY - 2011 UR - https://vinar.vin.bg.ac.rs/handle/123456789/4495 AB - Objectives: The incidence of non-AIDS-defining cancer is remarkably higher in HIV-infected than in the general population. In contrast, breast cancer risk is significantly reduced in the HIV-infected population. The molecular mechanisms underlying the phenomenon of suppression of breast cancer in the HIV-infected population may serve as a basis for development of a new platform for prevention and treatment of breast cancer. Hypothesis: Various evidences indicate that vasoactive intestinal peptide (VIP) plays an important role in growth, and differentiation of breast cancer. We previously showed (i) that natural antibodies recognizing VIP and the gp120-derived peptide NTM significantly contribute to the control of HIV disease progression by suppression of VIP-like activity of HIV-1 gp120 and (ii) that physical exercise stimulates production of these natural antibodies. These findings suggest that natural anti-VIP/NTM antibodies could contribute to a decrease of breast cancer in the HIV-infected population by suppression of VIP, which may play a pro/oncogenic function. Aerobic exercise which stimulates production of anti-VIP/NTM antibodies could be used as prevention and supportive treatment of breast cancer. Impact: Immunotherapy based on natural anti-VIP/NTM antibodies could serve as an effective adjunct therapy for the treatment of breast cancer. Similarly, aerobic exercise, which stimulates production of these antibodies, should be considered as an inexpensive and safe preventive and supportive breast cancer therapy. Natural anti-VIP/NTM antibodies also represent promising prognostic marker for breast cancer. (C) 2011 Elsevier Ltd. All rights reserved. T2 - Medical Hypotheses T1 - Can natural antibodies to VIP or VIP-like HIV-1 glycoprotein facilitate prevention and supportive treatment of breast cancer? VL - 77 IS - 3 SP - 404 EP - 408 DO - 10.1016/j.mehy.2011.05.030 ER -
@article{ author = "Veljković, Milena and Branch, Donald R. and Dopsaj, Violeta and Veljković, Veljko and Veljković, Nevena V. and Glišić, Sanja and Colombatti, Alfonso", year = "2011", abstract = "Objectives: The incidence of non-AIDS-defining cancer is remarkably higher in HIV-infected than in the general population. In contrast, breast cancer risk is significantly reduced in the HIV-infected population. The molecular mechanisms underlying the phenomenon of suppression of breast cancer in the HIV-infected population may serve as a basis for development of a new platform for prevention and treatment of breast cancer. Hypothesis: Various evidences indicate that vasoactive intestinal peptide (VIP) plays an important role in growth, and differentiation of breast cancer. We previously showed (i) that natural antibodies recognizing VIP and the gp120-derived peptide NTM significantly contribute to the control of HIV disease progression by suppression of VIP-like activity of HIV-1 gp120 and (ii) that physical exercise stimulates production of these natural antibodies. These findings suggest that natural anti-VIP/NTM antibodies could contribute to a decrease of breast cancer in the HIV-infected population by suppression of VIP, which may play a pro/oncogenic function. Aerobic exercise which stimulates production of anti-VIP/NTM antibodies could be used as prevention and supportive treatment of breast cancer. Impact: Immunotherapy based on natural anti-VIP/NTM antibodies could serve as an effective adjunct therapy for the treatment of breast cancer. Similarly, aerobic exercise, which stimulates production of these antibodies, should be considered as an inexpensive and safe preventive and supportive breast cancer therapy. Natural anti-VIP/NTM antibodies also represent promising prognostic marker for breast cancer. (C) 2011 Elsevier Ltd. All rights reserved.", journal = "Medical Hypotheses", title = "Can natural antibodies to VIP or VIP-like HIV-1 glycoprotein facilitate prevention and supportive treatment of breast cancer?", volume = "77", number = "3", pages = "404-408", doi = "10.1016/j.mehy.2011.05.030" }
Veljković, M., Branch, D. R., Dopsaj, V., Veljković, V., Veljković, N. V., Glišić, S.,& Colombatti, A.. (2011). Can natural antibodies to VIP or VIP-like HIV-1 glycoprotein facilitate prevention and supportive treatment of breast cancer?. in Medical Hypotheses, 77(3), 404-408. https://doi.org/10.1016/j.mehy.2011.05.030
Veljković M, Branch DR, Dopsaj V, Veljković V, Veljković NV, Glišić S, Colombatti A. Can natural antibodies to VIP or VIP-like HIV-1 glycoprotein facilitate prevention and supportive treatment of breast cancer?. in Medical Hypotheses. 2011;77(3):404-408. doi:10.1016/j.mehy.2011.05.030 .
Veljković, Milena, Branch, Donald R., Dopsaj, Violeta, Veljković, Veljko, Veljković, Nevena V., Glišić, Sanja, Colombatti, Alfonso, "Can natural antibodies to VIP or VIP-like HIV-1 glycoprotein facilitate prevention and supportive treatment of breast cancer?" in Medical Hypotheses, 77, no. 3 (2011):404-408, https://doi.org/10.1016/j.mehy.2011.05.030 . .